Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy

Brain

Volumn 140, Issue 1, 2017, Pages 184-200

  Laurent, Cyril ^a   Dorothée, Guillaume ^b,c   Hunot, Stéphane ^c,d,e,f   Martin, Elodie ^c,d,e,f   Monnet, Yann ^c,d,e,f   Duchamp, Marie ^b,c   Dong, Yuan ^b,c   Légeron, François Pierre ^c,d,e,f   Leboucher, Antoine ^a   Burnouf, Sylvie ^a   Faivre, Emilie ^a   Carvalho, Kévin ^a   Caillierez, Raphaëlle ^a   Zommer, Nadège ^a   Demeyer, Dominique ^a   Jouy, Nathalie ^a,g   Sazdovitch, Veronique ^d,e,h   Schraen Maschke, Susanna ^a   Delarasse, Cécile ^c,d,e,f   Buée, Luc ^a   Blum, David ^a   more..

^a UNIV LILLE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e CNRS   (France)

^f INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^g UAR2014 Us 41 Plateformes Lilloises en Biol S BioImaging Ctr Lille   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemokines; Frontotemporal lobar degeneration; Neuroinflammation; T cells; Tauopathy

Indexed keywords

CD3 ANTIBODY; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TAU PROTEIN; VON WILLEBRAND FACTOR; ANTIBODY; CD3 ANTIGEN; CHEMOKINE;

ADAPTIVE IMMUNITY; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOWN REGULATION; FEMALE; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MACROGLIA; MALE; MICROGLIA; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; T CELL DEPLETION; T LYMPHOCYTE; TAUOPATHY; UPREGULATION; Y-MAZE TEST; ANIMAL; BRAIN CORTEX; C57BL MOUSE; COGNITIVE DYSFUNCTION; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; TAUOPATHIES; TRANSGENIC MOUSE;

AGED; ANIMALS; ANTIBODIES; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CEREBRAL CORTEX; CHEMOKINES; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; TAUOPATHIES;

EID: 85021857903     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww270     Document Type: Article

References (69)

1. Ahmed T, Blum D, Burnouf S, Demeyer D, Buee-Scherrer V, D'Hooge R, et al. Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. Neurobiol Aging 2015; 36: 730-9.
2. Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 2015; 18: 1584-93.
3. Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, et al. Breaking immune tolerance by targeting Foxp3( + ) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun 2015; 6: 7967.
4. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat Med 2016; 22: 135-7.
5. Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, et al. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis 2011; 43: 486-94.
6. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165: 1643-52.
7. Bellucci A, Bugiani O, Ghetti B, Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 2011; 8: 221-9.
8. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68: 19-31.
9. Blair LJ, Frauen HD, Zhang B, Nordhues BA, Bijan S, Lin YC, et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun 2015; 3: 8.
10. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70: 960-9.
11. Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA. IFN-g Production by amyloid b-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol 2013; 190: 2241-51.
12. Burlot MA, Braudeau J, Michaelsen-Preusse K, Potier B, Ayciriex S, Varin J, et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum Mol Genet 2015; 24: 5965-76.
13. Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A, et al. Hippocampal BDNF expression in a tau transgenic mouse model. Curr Alzheimer Res 2012; 9: 406-10.
14. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, et al. NMDA receptor dysfunction contributes to impaired brainderived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell 2013; 12: 11-23.
15. Caroni P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods 1997; 71: 3-9
16. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 2009; 34: 63-70.
17. Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells delay disease progression in Alzheimerlike pathology. Brain 2016; 139 (Pt 4): 1237-51.
18. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999; 52: 1158-65.
19. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997; 18: 267-73.
20. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, et al. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006; 23: 351-61.
21. Fazilleau N, Delarasse C, Motta I, Fillatreau S, Gougeon ML, Kourilsky P, et al. T cell repertoire diversity is required for relapses in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 4865-75.
22. Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH. An antigen-specific pathway for CD8 T cells across the bloodbrain barrier. J Exp Med 2007; 204: 2023-30.
23. Garwood CJ, Cooper JD, Hanger DP, Noble W. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry 2010; 1: 136.
24. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 2009; 23: 2502-13.
25. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999; 20: 573-9.
26. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-27.
27. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388-405.
28. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712-16.
29. Jaerve A, Muller HW. Chemokines in CNS injury and repair. Cell Tissue Res 2012; 349: 229-48.
30. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010; 5: e13950.
31. Jones RS, Lynch MA. How dependent is synaptic plasticity on microglial phenotype? Neuropharmacology 2015; 96 (Pt A): 3-10.
32. Kwan WH, van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res 2012; 54: 247-53.
33. Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010; 20: 1107-18.
34. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-8.
35. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, et al. Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 2014; 35: 2079-90.
36. Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry 2016; 21: 97-107.
37. Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, et al. Detrimental effects of diet-induced obesity on t pathology are independent of insulin resistance in t transgenic mice. Diabetes 2013; 62: 1681-8.
38. Liblau RS, Gonzalez-Dunia D, Wiendl H, Zipp F. Neurons as targets for T cells in the nervous system. Trends Neurosci 2013; 36: 315-24.
39. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, et al. TLR2 is a primary receptor for Alzheimer's amyloid b peptide to trigger neuroinflammatory activation. J Immunol 2012; 188: 1098-107.
40. Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging 2015; 36: 81-9.
41. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, et al. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007; 28: 485-96.
42. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
43. Marciniak E, Faivre E, Dutar P, Alves Pires C, Demeyer D, Caillierez R, et al. The Chemokine MIP-1a/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci Rep 2015; 5: 15862.
44. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-9.
45. Minatohara K, Akiyoshi M, Okuno H. Role of immediate-early genes in synaptic plasticity and neuronal ensembles underlying the memory trace. Front Mol Neurosci 2016; 8: 78.
46. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112: 415-22.
47. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, et al. Abeta-induced meningoencephalitis is IFN-gammadependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5048-53.
48. Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 2013; 34: 1540-8.
49. Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez FJ, Pantano P, Obriot H, et al. Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation. Acta Neuropathol Comm 2016; 4: 74.
50. Patterson SL. Immune dysregulation and cognitive vulnerability in the aging brain: interactions of microglia, IL-1b, BDNF and synaptic plasticity. Neuropharmacology 2015; 96 (Pt A): 11-18
51. Pool M, Rambaldi I, Darlington PJ, Wright MC, Fournier AE, Bar-Or A. Neurite outgrowth is differentially impacted by distinct immune cell subsets. Mol Cell Neurosci 2012; 49: 68-76.
52. Qiao H, Foote M, Graham K, Wu Y, Zhou Y. 14-3-3 proteins are required for hippocampal long-term potentiation and associative learning and memory. J Neurosci 2014; 34: 4801-8.
53. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system:relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988; 9: 339-49
54. Rosset MB, Lui G, Dansokho C, Chaigneau T, Dorothee G. Vaccineinduced Ab-specific CD8 + T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease. J Neuroinflamm 2015; 12: 95.
55. Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, et al. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L. Brain Res 2008; 1214: 159-68.
56. Sauer BM, Schmalstieg WF, Howe CL. Axons are injured by antigenspecific CD8( + ) T cells through a MHC class I-and granzyme Bdependent mechanism. Neurobiol Dis 2013; 59: 194-205.
57. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 2006; 169: 599-616.
58. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, et al. Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008; 5: 207-224.
59. Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 2013; 38: 555-69.
60. Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 2005; 25: 11125-32.
61. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 2002; 124: 83-92.
62. Trifilo MJ, Bergmann CC, Kuziel WA, Lane TE. CC chemokine ligand 3 (CCL3) regulates CD8( + )-T-cell effector function and migration following viral infection. J Virol 2003; 77: 4004-14.
63. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012; 9: 397-405.
64. Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, et al. Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem 2011; 95: 296-304.
65. Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D, et al. Progressive age-related cognitive decline in tau mice. J Alzheimers Dis 2013; 37: 777-88.
66. Vidal M, Morris R, Grosveld F, Spanopoulou E. Tissue-specific control elements of the Thy-1 gene. EMBO J 1990; 9: 833-40
67. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010; 120: 1368-79.
68. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-51.
69. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-b42 immunization. Brain 2013; 136: 2677-96.